{
    "clinical_study": {
        "@rank": "132839", 
        "acronym": "MDT-2113 SFA", 
        "arm_group": [
            {
                "arm_group_label": "MDT-2113 Drug-Eluting Balloon", 
                "arm_group_type": "Experimental", 
                "description": "Paclitaxel drug-eluting angioplasty balloon"
            }, 
            {
                "arm_group_label": "Standard angioplasty balloon", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard PTA balloon without Paclitaxel drug-elution"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to assess the safety and efficacy of MDT-2113 for the\n      interventional treatment of de novo and non-stented restenotic lesions in the superficial\n      femoral artery (SFA) and the proximal popliteal artery (PPA) as compared to treatment with\n      standard percutaneous transluminal angioplasty (PTA)."
        }, 
        "brief_title": "MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Femoral Artery Stenosis", 
            "Popliteal Artery Stenosis", 
            "Femoral Artery Occlusion", 
            "Popliteal Artery Occlusion"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Constriction, Pathologic", 
                "Arterial Occlusive Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: \u2265 20 years and \u2264 85 years\n\n          -  Documented ischemia with Rutherford classification 2, 3, or 4\n\n          -  Able to walk without assistive devices\n\n          -  Target lesion is in the SFA and/or PPA above the knee\n\n          -  Target lesion consists of a single de novo or non-stented restenotic lesion (or\n             tandem lesions) or is a combination lesion that meets the following criteria:\n\n               1. \u2265 70% and < 100% occluded with total lesion length \u2265 40 mm and \u2264 200  mm\n\n               2. 100% occluded with total lesion length \u2264100 mm\n\n               3. Combination lesions must have total lesion length \u226540 mm and \u2264200 mm with an\n                  occluded segment that is \u2264 100 mm in length (by visual estimates)\n\n          -  Reference vessel diameter \u2265 4 mm and \u22647 mm (by visual estimate)\n\n          -  Angiographic evidence of adequate distal run-off through the foot\n\n        Exclusion Criteria:\n\n          -  Stroke or STEMI within the 3 months prior to enrollment\n\n          -  Either local or systemic thrombolytic therapy within the 48 hours prior to the index\n             procedure\n\n          -  Inability to tolerate oral anticoagulation therapy (blood thinners such as warfarin)\n             while on concomitant dual antiplatelet therapy (DAPT)\n\n          -  Known allergies or sensitivities to heparin, aspirin (ASA), other\n             anticoagulant/antiplatelet therapies or to paclitaxel, or an allergy to contrast\n             media that cannot be adequately pre-treated prior to the index procedure\n\n          -  Chronic renal insufficiency\n\n          -  Subject is enrolled in another investigational device, drug, or biologic study\n\n          -  Any major surgical procedure or intervention performed within the 30-day period prior\n             to or post index procedure\n\n          -  Contralateral SFA/PPA disease requiring treatment in the same setting as index\n             procedure\n\n          -  Failure to successfully cross the target lesion\n\n          -  Angiographic evidence of severe calcification\n\n          -  Target lesion known in advance of enrollment to require treatment with alternative\n             therapy such as stenting, laser, atherectomy, cryoplasty, brachytherapy, re-entry\n             devices, cutting balloons, scoring balloons; use of embolic protection devices is\n             also prohibited"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01947478", 
            "org_study_id": "10102118DOC"
        }, 
        "intervention": [
            {
                "arm_group_label": "MDT-2113 Drug-Eluting Balloon", 
                "description": "Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm", 
                "intervention_name": "MDT-2113 Drug-Eluting Balloon", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Standard angioplasty balloon", 
                "description": "Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm", 
                "intervention_name": "Standard angioplasty balloon", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Drug-Eluting Angioplasty Balloon", 
            "Drug Coated Angioplasty Balloon", 
            "Peripheral Artery Disease", 
            "Experimental", 
            "Percutaneous Transluminal Angioplasty (PTA)"
        ], 
        "lastchanged_date": "January 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Amagasaki", 
                    "country": "Japan", 
                    "state": "Hyogo"
                }, 
                "name": "Kansai Rosai Hospital"
            }, 
            "investigator": {
                "last_name": "Osamu Iida, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Trial of MDT-2113 Drug-Eluting Balloon (DEB) vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery", 
        "overall_contact": {
            "email": "rs.medtroniccardiovascularclinicaltrials@medtronic.com", 
            "last_name": "P Yamaguchi"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary patency is defined as freedom from clinically-driven target lesion revascularization (TLR) and freedom from restenosis as determined by duplex ultrasound (DUS)", 
            "measure": "Efficacy: Primary patency", 
            "safety_issue": "Yes", 
            "time_frame": "12 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01947478"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Freedom from device- and procedure-related death through 30 days post-procedure, and freedom from target limb major amputation and clinically-driven target vessel revascularization (TVR)", 
            "measure": "Primary safety endpoint", 
            "safety_issue": "Yes", 
            "time_frame": "12 month"
        }, 
        "source": "Medtronic Endovascular", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medtronic Endovascular", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}